BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34696930)

  • 1. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.
    Tedesco-Silva H; Saliba F; Barten MJ; De Simone P; Potena L; Gottlieb J; Gawai A; Bernhardt P; Pascual J
    Transplant Rev (Orlando); 2022 Jan; 36(1):100655. PubMed ID: 34696930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.
    Ivulich S; Paul E; Kirkpatrick C; Dooley M; Snell G
    Transpl Int; 2023; 36():10704. PubMed ID: 36744051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
    J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
    [No Abstract]   [Full Text] [Related]  

  • 9. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
    Zhang W; Fung J
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?
    Witzke O; Sommerer C; Arns W
    Transplant Rev (Orlando); 2016 Jan; 30(1):3-12. PubMed ID: 26603484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of everolimus in liver transplantation.
    Ganschow R; Pollok JM; Jankofsky M; Junge G
    Clin Exp Gastroenterol; 2014; 7():329-43. PubMed ID: 25214801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bzeizi KI; Smith R; Albenmousa A; Dama M; Aba-Alkhail F; Jalan R; Broering D
    Transplant Proc; 2021; 53(1):148-158. PubMed ID: 33390288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
    Gude E; Gullestad L; Andreassen AK
    Curr Opin Organ Transplant; 2017 Jun; 22(3):198-206. PubMed ID: 28463861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H; Midtvedt K; Åsberg A
    Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.
    Pascual J; Berger SP; Chadban SJ; Citterio F; Kamar N; Hesselink DA; Legendre C; Eisenberger U; Oppenheimer F; Russ GR; Sommerer C; Rigotti P; Srinivas TR; Watarai Y; Henry ML; Vincenti F; Tedesco-Silva H
    Transplant Rev (Orlando); 2019 Oct; 33(4):191-199. PubMed ID: 31377099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.